Frontiers in Clinical Drug Research - Anti-Cancer Agents

Frontiers in Clinical Drug Research - Anti-Cancer Agents

Volume: 5

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for ...
[view complete introduction]

US $

*(Excluding Mailing and Handling)

Ros-Mediated Induction of Apoptosis in Breast Cancer Cells

Pp. 113-121 (9)

DOI: 10.2174/9789811405150119050007

Author(s): Işıl Yıldırım


Due to an excessive production of ROS production by the cell's loss of its ability to metabolize, an oxidative stress is expressed. An excessive accumulation of ROS alters not only the biochemical but also genetic and epigenetic mechanisms. These changes could lead to cancer development. In previous studies, it was determined that ROS plays a critical role and the therapy target has also been discussed. So, throughout this manuscript, I aimed to review the role of ROS and its associated signaling pathways in the initiation and progression and apoptosis of breast cancer. This fine distinction of the ROS action depends not only on pro-apoptotic agents and anti-apoptotic agents; ROS leads to the activation of several signaling pathways but also on the duration, type, dosage (concentration) and site of ROS generation and change gene expressions. This study will keep current on the relevant mechanisms of ROS-mediated apoptosis and will guide future studies.


ROS, Oxidative Stress, Apoptosis, Capsase, Breast Cancer, MCF7 cells, MDA-MB-231 cells, anticancer drugs, Molecular mechanisms.